EVEXTA-BIO
19.6.2024 17:08:31 CEST | Business Wire | Press release
Evexta Bio SA, a clinical-stage biotechnology company focused on developing first-in-class therapies in oncology, announces the appointment of Shawn M. Leland, PharmD, RPh as Chairman of the Board of Directors.
Shawn is an accomplished pharmaceutical and biotechnology professional with more than 15 years of experience in the industry. Throughout his career, Shawn has successfully advanced novel oncology assets and programs, raised substantial capital for various ventures, negotiated major global licensing agreements, and established strategic partnerships. His extensive experience in leading biotech startups, raising capital and executing strategic collaborations will be a major benefit to Evexta Bio in its growth and corporate development strategy.
Most recently, Shawn was the Interim CEO and Board Director of ForeBio, where he led the company through a phase 2 study with registrational intent and closed a $75M Series D financing.
In July 2019, Shawn founded Elevation Oncology, where he served as Chief Business Officer and Board Director, and later as CEO until January 2023. During his mandate, the company advanced multiple novel targeted oncology assets. Shawn raised over $200M in capital, which included a $100M IPO. Shawn grew Elevation Oncology from zero to more than 50 employees.
Shawn was Head of Business Development at Verastem Oncology from 2017 – 2019 and Argos Therapeutics from 2013 – 2017 where he played a pivotal role in each company’s corporate development strategy leading multiple partnerships and licensing transactions. Shawn started his career with pharmaceutical and biotechnology companies, ARIAD Pharmaceuticals and Eli Lilly. Shawn holds a PharmD from Albany College of Pharmacy.
Alain Chevallier, former Chairman of the board of Directors of Evexta Bio, said: “I'm pleased to be handing over the chairmanship to a great professional of the oncology and biotech field as Shawn, who brings new valuable perspectives to Evexta Bio, and I will continue, as Vice-Chairman, to be fully committed to the success of the Company.”
Scott Filosi, CEO of Evexta Bio added: “I am delighted to welcome Shawn as Chairman of the Board of Directors. His experience and expertise in oncology and strategic development of biotechnology companies are real assets for Evexta Bio. I’m looking forward to working with him to accelerate the mission of Evexta Bio.”
Shawn M. Leland, Chairman of the Board of Directors of Evexta Bio, said: "I’m looking forward to joining the team of Evexta Bio in such a pivotal moment of its development. Evexta Bio has tremendous potential and I thank the members of the Board of Directors for their trust.”
About Evexta Bio (https://www.evextabio.com)
Evexta Bio is a biopharmaceutical company exploring the new frontiers of oncology in search of daring novel therapeutic approaches with the potential to save lives. Now, in the clinic, the company is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications:
- Rupitasertib, an optimized S6K inhibitor with efficient AKT1/AKT3 control of compensatory AKT feed-back loop. The oral anti-tumor agent is expected to enter phase 2 clinical trial in ESR1mt ER+ HER2- advanced breast cancer.
- EVX020, a sole-in-class KIF20A kinesin inhibitor having shown potent nonclinical efficacy in hematological and solid tumor models. Two strategies are under assessment, development of EVX020 as a prodrug and as a payload for antibody-drug conjugate (ADC).
Founded by Truffle Capital, supported by Merck KGaA (Darmstadt, Germany) as shareholder, Evexta Bio has forged alliances with leaders in academia and industry, including CNRS, Paoli-Calmettes Institute (Marseille, France) and Merck KGaA. The company is supported by seasoned management team, board of directors and medical advisory board.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619024966/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
Xsolla Launches Game Biz Institute, an Editorial Platform Where Industry Practitioners Explain the Business of Games27.8.2026 17:32:00 CEST | Press release
New Platform Pairs Independent Researchers and Industry Veterans with Xsolla Experts to Unpack Direct-to-Player Commerce, Monetization, Payments, and Player Retention Xsolla, a global commerce company, today announced the launch of Game Biz Institute (GBI), an editorial platform where named industry practitioners and researchers examine the commercial layer of games: direct-to-player distribution, payments, monetization, user acquisition, and retention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827362663/en/ Graphic: Xsolla Game design has a curriculum. The business of games does not. Engines, pipelines, production, and narrative are taught at hundreds of universities, while the commercial machinery that determines whether good work becomes a durable company is still learned through expensive trial and error, usually after the decisions that mattered have already been made. GBI was built to close that gap by publishi
Star Wars Zero Company™ Now Available On PC, PlayStation 5 and XBOX Series Consoles27.8.2026 17:00:00 CEST | Press release
Bit Reactor’s Debut Title Combines Tactical Depth and Cinematic Elegance for a New Star Wars StoryWatch the Final Trailer to Witness What’s at Stake in the Galaxy Electronic Arts Inc. and Bit Reactor, in collaboration with Lucasfilm Games, announced today that Star Wars Zero Company™, a single-player turn-based tactics game set in the twilight of the Clone Wars™, is now available for PC via the EA app, Steam, and Epic Games Store, and PlayStation®5 and XBOX Series consoles. In Star Wars Zero Company, former Republic officer Hawks and Zero Company, an elite squad of unconventional professionals for hire, are recruited for an operation by Republic Intelligence. From ex-nobles to ex-cons, they now share one mission: Stop the Infinite Coil, a Separatist-aligned cult, and their leader Kundri Fathom before the deadly Shadow Plague consumes the galaxy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012810/en/ https://www.yout
Rehlko Joins Wisconsin Data Center Coalition as Newest Energy Resilience Member, Reinforcing Its Role at the Center of AI and Digital Infrastructure Growth27.8.2026 15:15:00 CEST | Press release
Global Energy Resilience Leader Reinforces Its Role at the Center of AI and Digital Infrastructure Growth Through Mission-Critical Power Expertise Rehlko, a global industrial energy resilience platform providing custom-engineered, integrated power solutions for mission-critical infrastructure worldwide, today announced it has joined the Wisconsin Data Center Coalition (WIDCC) as the organization's newest energy resilience member. The membership reflects Rehlko's commitment to advancing Wisconsin's role as a leader in responsible AI infrastructure development, built on reliable and scalable power. Rapid growth in hyperscale and enterprise data center investment is reshaping markets across the world, and Rehlko is building the power infrastructure that makes it possible. Sitting at the intersection of the structural forces driving AI infrastructure expansion, grid reliability, and accelerating electrification, Rehlko brings more than a century of engineering depth and lifecycle capabilit
GenNx360 Capital Partners Closes Fourth Flagship Fund at $865 Million27.8.2026 14:30:00 CEST | Press release
Fund IV success is the result of two decades of proven performance backing lower middle market industrial services and business services companies GenNx360 Capital Partners (“GenNx360” or “the Firm”), a New York City-based private equity firm investing in U.S. lower middle market industrial services and business services companies, today announced the successful closing of GenNx360 Capital Partners IV, L.P. (“Fund IV” or “the Fund”), with $865 million in commitments, exceeding its target. Fund IV is the largest fund raised in GenNx360’s history. Fund IV was supported by a diverse group of existing and new investors including leading pensions, asset managers, insurance companies, foundations, and family offices, reflecting conviction in the firm’s disciplined investment approach, operational value creation model, and tenured, diverse team. Fund IV will continue GenNx360’s differentiated strategy of partnering with lower middle market founders and management teams to scale essential serv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom